GreenLight Biosciences Holdings PBC (GRNA) Stock News
NASDAQ:GRNA - Nasdaq - US39536G1058 - Common Stock - Currency: USD
GRNA Latest News, Press Relases and Analysis
GreenLight Announces Completion of Merger with Fall Line Endurance Fund
GreenLight Announces Completion of Merger with Fall Line Endurance Fund
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced...
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023...
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of GreenLight Biosciences Holdings and Encourages Long-Term GRNA / ENVI Shareholders to Contact the Firm
/PRNewswire/ -- Kaskela Law LLC announces that it is investigating GreenLight Biosciences Holdings (NASDAQ: GRNA) ("GreenLight") on behalf of the company's...
Mentions: ENVI
GRNA ALERT: Levi & Korsinsky, LLP Announces an Investigation of Greenlight Biosciences
/PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who hold Greenlight Biosciences Holdings PBC...
Shareholder Alert: Ademi LLP investigates whether GreenLight Biosciences Holdings, PBC has obtained a Fair Price in its transaction with Fall Line
/PRNewswire/ -- Ademi LLP is investigating GreenLight (NASDAQ: GRNA) for possible breaches of fiduciary duty and other violations of law in its transaction...
GreenLight Biosciences 36% higher merger Fall Line Endurance Fund (NASDAQ:GRNA)
GreenLight Biosciences (GRNA) to be acquired by a group of buyers led by Fall Line Capital in an all-cash transaction valued at $45.5M.Fall Line, together with its affiliates, agreed...
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced...
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable...
GreenLight Biosciences Releases Inaugural Sustainability Report
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential...
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving...
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect...
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital...
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase...
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine...